A derivative of Brevianamide F,（3 S,8 a R）-3-（（1-allyl-1 H-3-indolyl）methyl）-hexahy-dropyrrolo[1,2-a]pyrazine-1,4-dione, was synthesized and characterized by 1 H NMR, 13 C NMR and confirmed by X-ray crystal stru...A derivative of Brevianamide F,（3 S,8 a R）-3-（（1-allyl-1 H-3-indolyl）methyl）-hexahy-dropyrrolo[1,2-a]pyrazine-1,4-dione, was synthesized and characterized by 1 H NMR, 13 C NMR and confirmed by X-ray crystal structure analysis. This compound crystallizes in orthorhombic system, space group P212121 with a = 9.59590（10）, b = 12.70430（10）, c = 14.5425（2） ?, V = 1772.86（3） ?3, Z = 4, μ（CuK α） = 0.712 mm-1, Dc = 1.279 g/cm3, 16019 reflections measured（9.24 o≤2θ≤147.28°）, 3524 unique（Rint = 0.0309, Rsigma = 0.0175） which were used in all calculations. The final R = 0.0567（I > 2σ（I）） and w R = 0.1411（all data）. The structure exhibits intermolecular hydrogen bonds typed O–H…O, leading to the formation of one-dimensional chains. The title compound was tested for inhibitory activity toward B-16, C6, RM-1 and BV-2 cancer cell lines.展开更多
基金financially sponsored by the Natural Science Foundation of Hebei Province(No.B2015208134)
文摘A derivative of Brevianamide F,（3 S,8 a R）-3-（（1-allyl-1 H-3-indolyl）methyl）-hexahy-dropyrrolo[1,2-a]pyrazine-1,4-dione, was synthesized and characterized by 1 H NMR, 13 C NMR and confirmed by X-ray crystal structure analysis. This compound crystallizes in orthorhombic system, space group P212121 with a = 9.59590（10）, b = 12.70430（10）, c = 14.5425（2） ?, V = 1772.86（3） ?3, Z = 4, μ（CuK α） = 0.712 mm-1, Dc = 1.279 g/cm3, 16019 reflections measured（9.24 o≤2θ≤147.28°）, 3524 unique（Rint = 0.0309, Rsigma = 0.0175） which were used in all calculations. The final R = 0.0567（I > 2σ（I）） and w R = 0.1411（all data）. The structure exhibits intermolecular hydrogen bonds typed O–H…O, leading to the formation of one-dimensional chains. The title compound was tested for inhibitory activity toward B-16, C6, RM-1 and BV-2 cancer cell lines.
